DK1841316T3 - CCN3-protein til anvendelse ved behandling og diagnose af nyresygdomme - Google Patents

CCN3-protein til anvendelse ved behandling og diagnose af nyresygdomme

Info

Publication number
DK1841316T3
DK1841316T3 DK06717966.3T DK06717966T DK1841316T3 DK 1841316 T3 DK1841316 T3 DK 1841316T3 DK 06717966 T DK06717966 T DK 06717966T DK 1841316 T3 DK1841316 T3 DK 1841316T3
Authority
DK
Denmark
Prior art keywords
ccn3
protein
diseases
treatment
kidney disease
Prior art date
Application number
DK06717966.3T
Other languages
English (en)
Inventor
Bruce L Riser
Bernard Perbal
Original Assignee
Univ Rosalind Franklin Medicine & Science
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Rosalind Franklin Medicine & Science filed Critical Univ Rosalind Franklin Medicine & Science
Application granted granted Critical
Publication of DK1841316T3 publication Critical patent/DK1841316T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Vascular Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
DK06717966.3T 2005-01-10 2006-01-10 CCN3-protein til anvendelse ved behandling og diagnose af nyresygdomme DK1841316T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64272805P 2005-01-10 2005-01-10
PCT/US2006/000833 WO2006074452A2 (en) 2005-01-10 2006-01-10 Regulation of ccn2 by ccn3 and its therapeutic and diagnostic potential in fibrosis, sclerosis and other diseases

Publications (1)

Publication Number Publication Date
DK1841316T3 true DK1841316T3 (da) 2011-08-08

Family

ID=36648253

Family Applications (1)

Application Number Title Priority Date Filing Date
DK06717966.3T DK1841316T3 (da) 2005-01-10 2006-01-10 CCN3-protein til anvendelse ved behandling og diagnose af nyresygdomme

Country Status (10)

Country Link
EP (1) EP1841316B1 (da)
JP (1) JP4834677B2 (da)
AT (1) ATE506961T1 (da)
AU (1) AU2006203851B8 (da)
CA (1) CA2597794A1 (da)
DE (1) DE602006021534D1 (da)
DK (1) DK1841316T3 (da)
ES (1) ES2395260T3 (da)
PL (1) PL1841316T3 (da)
WO (1) WO2006074452A2 (da)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0618748D0 (en) * 2006-09-22 2006-11-01 Univ Belfast Peptide
CN104076152B (zh) * 2008-10-21 2017-04-19 阿斯图特医药公司 用于诊断和预后肾损伤和肾衰竭的方法和组合物
JP5939584B2 (ja) * 2010-04-02 2016-06-22 ロザリンド フランクリン ユニバーシティー オブ メディスン アンド サイエンス 治療用ｃｃｎ３ペプチドおよびそれらの類似体
US9114112B2 (en) * 2010-04-02 2015-08-25 Rosalind Franklin University Of Medicine And Science CCN3 and CCN3 peptides and analogs thereof for therapeutic uses
WO2011134063A1 (en) * 2010-04-26 2011-11-03 UNIVERSITé LAVAL Ccn3 and uses thereof against metabolic syndrome- associated disorders
US10028906B2 (en) 2016-03-22 2018-07-24 Rosalind Franklin University Of Medicine And Science Method and kit for treating a solid tumor and associated desmoplasia
EP3711772A1 (en) * 2019-03-20 2020-09-23 Oslo Universitetssykehus HF Recombinant proteins and fusion proteins

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040009940A1 (en) * 2000-10-20 2004-01-15 Coleman Michael E. Gene delivery formulations and methods for treatment of ischemic conditions
FR2825928B1 (fr) * 2001-06-18 2004-04-02 Ecole Norm Superieure Cachan Composition pharmaceutique pour le diagnostic, la prevention ou le traitement d'une pathologie tumorale, comprenant un agent modulateur de l'etat polymerisation de l'actine
EP1382347A1 (en) * 2002-07-17 2004-01-21 UNIVERSITE PARIS 7 - Denis DIDEROT Use of CCN protein family members for the treatment of disorder associated to an altered calcium and/or sodium flux
WO2004090109A2 (en) * 2003-03-31 2004-10-21 Munin Corporation Ccn3 compositions and methods
WO2006036962A2 (en) * 2004-09-28 2006-04-06 Lau Lester F Compositions and methods for modulating tissue regeneration and chemotactic responses

Also Published As

Publication number Publication date
WO2006074452A2 (en) 2006-07-13
ES2395260T3 (es) 2013-02-11
AU2006203851B8 (en) 2012-11-15
JP2008526890A (ja) 2008-07-24
CA2597794A1 (en) 2006-07-13
JP4834677B2 (ja) 2011-12-14
ATE506961T1 (de) 2011-05-15
WO2006074452A3 (en) 2006-11-16
EP1841316B1 (en) 2011-04-27
AU2006203851A1 (en) 2006-07-13
DE602006021534D1 (de) 2011-06-09
EP1841316A2 (en) 2007-10-10
EP1841316A4 (en) 2008-07-09
PL1841316T3 (pl) 2011-09-30
AU2006203851B2 (en) 2012-04-12

Similar Documents

Publication Publication Date Title
DK1841316T3 (da) CCN3-protein til anvendelse ved behandling og diagnose af nyresygdomme
NO20065847L (no) Difenylimidazopyrimidiner og -imidazolaminer som inhibitorer av B-sekretase
EA200900177A1 (ru) Замещенные ациланилиды и способы их применения
EA200700886A1 (ru) Соединение тиадиазола и его применение
BR0308928A (pt) Uso de toxina botulìnica para o tratamento de doenças cardiovasculares, bem como composição para uso em um procedimento cardiovascular
HK1215960A1 (zh) 用於治療視網膜變性疾病的改良方式
NO20070247L (no) Amino-5,5-difenylimidazolonderivater for inhibisjon av beta-sekretase
NO20081972L (no) Generering og profilering av fulle humane hucal gull-deriverte terapeutiske antistoffer spesifikke for human CD38
EA201070636A1 (ru) Ингибирование рецептора белка, стимулирующего макрофаги (ron), и способы его лечения
EA200901263A1 (ru) Конденсированный аминопиридин в качестве ингибиторов hsp90
WO2009026657A8 (en) Flavonoid ppar agonists
NO20091413L (no) WNT-antagonister og deres anvendelse i diagnostiseringen og behandlingen av WNT-medierte forstyrrelser
TW200740844A (en) Novel MAdCAM antibodies
UA90698C2 (en) Triazole substituted aminobenzophenone compounds
TW200509892A (en) Novel aminobenzophenone compounds
EA201000644A1 (ru) Антитела для лечения и профилактики болезни альцгеймера и их применение
EA200700333A1 (ru) Терапевтические применения ингибиторов rtp801
NO20054371L (no) Somatostatin-dopamin kimaere analoger
EA200801842A1 (ru) Антитела против бета-амилоидного пептида
EA200971053A1 (ru) Способы лечения кожных язв
EA200801425A1 (ru) Диазепиноны
GB0523961D0 (en) The treatment of ophthalmic diseases
EA200702336A1 (ru) ПРИМЕНЕНИЕ 24-норУДХК
NO20093536L (no) Kombinasjonsterapi ved kreftbehandling som omfatter vinflunin og trastuzumab
EA200702634A1 (ru) Гуманизированные антитела, специфичные в отношении nogo-a, и их фармацевтические применения